Which lung cancer patients is Sutolaxib (AMG 510) suitable for and prediction of drug effects?

Sotorasib (AMG 510) is an oral KRAS G12C inhibitor and the world's first approved targeted drug targeting KRAS G12C mutations. KRASMutation is one of the most common driver gene mutations in non-small cell lung cancer (NSCLC), especially in patients with lung adenocarcinoma. In the past, treatment options for patients with KRAS mutations were limited, and traditional chemotherapy and immunotherapy were not effective. The advent of sotoracib has brought new treatment opportunities to this group of people with specific gene mutations, especially in patients with advanced or metastatic lung cancer, which has shown clear efficacy.

First of all, sotorasiib is mainly suitable for adult patients with locally advanced or metastatic non-small cell lung cancer who carry KRAS G12C mutations, and these patients have usually received at least one systemic therapy. Before use, the KRAS G12C mutation status must be clarified through genetic testing. This is a prerequisite for determining whether the patient is suitable for medication. Treatment with sotorasib is not recommended for patients who do not have this mutation or who carry other KRAS mutations. Therefore, standardized genetic testing is crucial for screening suitable populations.

Secondly, from the perspective of efficacy data, clinical studies show that sotoracib has a good objective response rate (ORR) and disease control rate (DCR) in patients with KRAS G12C mutation. Some research results show that the ORR can reach about 37%, the median progression-free survival (PFS) is about 6.8 months, and the remission of some patients can last for more than one year. Compared with traditional chemotherapy, sotoracib has the advantages of stronger targeting, faster onset of action, better tolerance, no need for intravenous infusion, and more convenient administration, which improves patients' quality of life.

Finally, the actual therapeutic effect of sotoracib is also affected by the patient's overall condition, tumor burden, whether it is accompanied by other mutations, and previous treatment regimens. For example, the efficacy of patients with STK11, TP53 and other gene mutations may be different. In addition, the presence of brain metastasis, liver function, etc. will also affect drug metabolism and efficacy. Therefore, a comprehensive evaluation should be conducted before use and an individualized treatment plan should be formulated to maximize the therapeutic value of sotorasib.

Reference materials:https://www.drugs.com/